Thu. 14 Mar 2024, 6:56am ET
Benzinga
Earnings, News
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $10.49 million which beat the analyst consensus estimate of $5.80 million by 80.79 percent. This is a 21.69 percent increase over sales of $8.62 million the same period last year.